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AbstrACt
Introduction Weight loss after bariatric surgery (BS) is 
often associated with improved cognition and structural 
brain recovery. However, improved cognition after BS 
is not always exhibited by patients, in fact, in some 
cases there is even a decline in cognition. Long-term 
consequences of BS weight loss, in terms of obesity 
and related diseases, can be hard to determine due to 
studies having short follow-up periods and small sample 
sizes. The aim of the BARICO study (BAriatric surgery 
Rijnstate and Radboudumc neuroImaging and Cognition in 
Obesity) is to determine the long-term effect of weight loss 
after BS on brain function and structure, using sensitive 
neuropsychological tests and (functional) MRI ((f)MRI). 
Secondary study endpoints are associated with changes 
in metabolic and inflammation status of adipose tissue, 
liver and gut, in relation to brain structure and function. 
Also, the possible correlation between weight loss, gut 
microbiota composition change and neuropsychological 
outcomes will be investigated.
Methods and analysis Data from 150 Dutch BS patients 
(ages between 35 and 55, men and women) will be 
collected at various time points between 2 months before 
and up to 10 years after surgery. Neuropsychological tests, 
questionnaires, blood, faeces and tissue samples will be 
collected before, during and after surgery to measure 
changes in cognition, microbiota, metabolic activity and 
inflammation over time. A subgroup of 75 participants 
will undergo (f)MRI in relation to executive functioning 
(determined by the Stroop task), grey and white matter 
volumes and cerebral blood flow. Regression analyses will 
be used to explore associations between weight loss and 
outcome measures.
Ethics and dissemination This study has been approved 
by the medical review ethics committee CMO Region 
Arnhem and Nijmegen (NL63493.091.17). Research 
findings will be published in peer-reviewed journals and at 
conferences.
trial registration number NTR7288. 
IntroduCtIon 
For over two decades, obesity-induced 
diseases, such as cardiovascular disease, and 
type 2 diabetes mellitus (T2DM), have been 
one of the major healthcare challenges of 
today’s society.1 Besides the well-known meta-
bolic complications, obesity may lead to struc-
tural brain changes, cognitive impairment 
and neurodegenerative diseases.2–5 Addi-
tionally, a direct relationship exists between 
increased body mass and cognitive impair-
ment.6–9 To improve and possibly reduce the 
amount of obesity-induced diseases, inhibit 
cognitive impairment and reduce neurode-
generative diseases, sustainable long-term 
weight loss in patients with obesity must be 
achieved. Non-surgical treatments for obesity, 
strengths and limitations of this study
 ► For the first time in bariatric research, neuroimaging, 
neuropsychological tests and metabolic and histo-
pathological parameters will be combined to inves-
tigate the effect of weight loss on brain function and 
structure after bariatric surgery.
 ► Collecting and investigating multiple metabolic pa-
rameters (obtained from blood, various tissue and 
microbiota) may help reveal the relationship, and 
underlying mechanisms, between obesity and brain 
function and structure.
 ► With a follow-up of 10 years after bariatric surgery, 
additional knowledge will be gathered on the long-
term effects of weight loss on cognitive function.
 ► Only bariatric surgery patients are included in this 
study, so whether the results are generalisable 
to patients with obesity in general will require fur-
ther investigation.
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such as dietary restriction and physical activity, often show 
disappointing long-term effects, especially in patients 
with morbid obesity (body mass index (BMI) above 
40 kg/m2).10 11 Bariatric surgery (BS) is known to a rapid 
and sustainable decrease in body mass. In particular, the 
commonly performed Roux-en-Y gastric bypass (RYGB) 
leads to rapid weight loss which is often accompanied by 
remission of T2DM, hypertension (HT) and dyslipidaemia 
(DL).12 13 RYGB is a restrictive and malabsorptive (for 
micronutrients) surgical procedure; it excludes the main 
part of the stomach, the duodenum and the first part of 
the jejunum from the passage of food, leading to, among 
others, hormonal and gut microbiota changes.14 15 Gut 
microbiota changes after RYGB comprise increases in gut 
microbiota diversity, increases in relative abundance of 
Actinobacteria and Firmicutes phyla and decreases in rela-
tive abundance of Bacteroidetes phylum. However, effects 
in reported studies are quite inconsistent and further 
research is needed.16 17 
Besides weight loss and remission of comorbidities, 
RYGB surgery is also associated with improved cognitive 
functions.18 19 This may be related to multiple metabolic 
parameters, such as systolic blood pressure or triglyceride 
concentrations.20 Metabolic complications may also 
arise in patients with obesity due to a disturbed interac-
tion between metabolic organs such as adipose tissue, 
liver and gut. This is especially a problem in mid-life 
(ages between 35 and 55) in which obesity has been 
reported to cause cognitive decline and increase risk for 
developing dementia. However, mechanisms involved in 
this organ-organ crosstalk are poorly understood.4 21–24 
First, one proposed mechanism is the altered signal-
ling of visceral and abdominal adipose tissue; adipose 
tissue acts as an independent endocrine organ releasing 
several hormones, proteins and cytokines, referred to as 
adipokines. Obesity is associated with dysfunctional white 
adipose tissue and therefore an imbalance in adipokines, 
such as increased levels of leptin and angiotensinogen, 
and low levels of adiponectin and omentin.25 26 Especially, 
visceral adipose tissue seems to produce unfavourable 
adipokines associated with more metabolic complications 
when compared with subcutaneous adipose tissue.27–30 
Importantly, the distribution of fat tissue depots differs 
between sexes. Overall, men accumulate more abdom-
inal and visceral fat than women.30 Moreover, women 
have a higher level of adipokines such as leptin and 
adiponectin.31 32 This disbalance in adipokines may 
induce inflammation in several organs such as the liver, 
gut and vascular endothelium. The latter causing athero-
sclerosis, ultimately leading to changes in cerebral blood 
flow (CBF).25
Second, signalling between, and within other organs, 
such as the liver, might be altered in patients with 
obesity. For example, the liver secretes hepatokines, 
such as insulin-like growth factor 1, selenoprotein P, 
leucocyte cell-derived chemotaxin, fetuin B and hepas-
socin, which may indirectly affect brain function and 
structure.33 34
Third, the gut microbiota composition in obese people 
differs from that of non-obese individuals, affecting 
metabolic processes, weight and obesity-related comor-
bidities.35 36 Microbiota is involved in adiposity and 
homeostasis but also influences energy balance via 
appetite and satiety signalling to the brain. Gut micro-
biota also affects the brain by producing (precursors of) 
neurotransmitters and short-chain fatty acids, or through 
cytokines via the immune system.37 38 BS leads to a fast 
change in gut microbiota composition through changes 
in food intake, intestinal modifications due to the surgery 
itself and metabolic improvements, eventually leading to 
changes in gut-brain communication.15 39 40 Hence, meta-
bolic organs, such as liver, gut and adipose tissue and 
gut microbiota, may constitute new therapeutic targets. 
Although long-term results are not yet clear, the gut 
microbiota has already become a target for antiobesity 
treatments.37
Obesity is associated with impaired CBF, which may 
lead to inadequate oxygen and energy supply in the brain 
and eventually loss of white and grey matter integrity.41 42 
Lower levels of CBF in the prefrontal cortex are associated 
with reduced performance on executive function and 
episodic memory tests.42 43 Even in the prodromal stages 
of Alzheimer’s disease, changes in CBF can be detected 
with arterial spin labelling (ASL), which may be used as 
a very early biomarker for neurodegenerative disorders.44 
However, the technique requires further optimisation 
and therefore several consortia are working on the imple-
mentation of ASL perfusion MRI for clinical applications 
to provide images of sufficient and diagnostic utility.45
Furthermore, obesity is associated with changes in grey 
and white matter, which can be visualised using diffusion 
tensor imaging (DTI) and voxel-based morphometry 
analyses based on T1-weighted scans.46 47 These struc-
tural changes are especially prominent in brain regions 
governing reward seeking, inhibitory control and appe-
tite.48 49 There are indications that rapid recovery of struc-
tural abnormalities occurs after BS, however long-term 
study data are lacking here.50 51
Additionally, impairment in attention span, execu-
tive function and memory are commonly reported in 
patients with obesity.18 19 Cognitive impairment revealed 
in obesity might be reversible and varies between cogni-
tive domains, however long-term follow-up studies are 
scarce. The Longitudinal Assessment of Bariatric Surgery 
parent project is the most extensive longitudinal study to 
date focusing on cognitive changes in patients after BS. 
Investigators showed lasting improvements 3 years after 
surgery in the cognitive domains of attention, executive 
function and memory.19
rationale
Cognitive benefits after BS are not equally exhibited 
across patients and cognitive domains. However, precise 
causes are still poorly understood, and underlying molec-
ular mechanisms remain elusive. From the relatively short 
follow-up duration and small samples of BS patients in the 
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studies reviewed, it is difficult to elaborate on the long-
term consequences of obesity and its related diseases. 
In this study, underlying mechanisms of obesity-related 
cognitive disorders will be investigated by longitudinal 
studies correlating cognition to brain changes, blood 
serum and plasma values, and gut microbiota composi-
tion. Lastly, metabolic and histopathological parameters 
(at the time point of surgery) will be obtained to study 
whether associations or correlations exist between obesi-
ty-associated metabolic dysfunctions of particular organs 
and brain function and structure. To our knowledge, this 
is the first study in humans investigating changes in brain 
structure and function, and changes in adipose tissue, 
liver function and the gut microbiome, after BS-induced 
weight loss. Additionally, this is the first study in bariatric 
research combining neuroimaging, cognition and exten-
sive profiling of biological markers.
The primary aim of the BARICO study (BAriatric 
surgery Rijnstate and Radboudumc neuroImaging and 
Cognition in Obesity) is to determine the long-term effect 
of weight loss on measures of brain function and struc-
ture after BS. The secondary aim is to provide mecha-
nism-based rationales responsible for functional and 
structural decline in obese individuals. Therefore, the 
metabolic and inflammation status of organ biopsies will 
be determined together with molecular signatures via 
blood plasma/serum analyses. Furthermore, gut micro-
biota composition will be monitored over time to gain 
knowledge about the gut-brain axis.
This study will contribute to the development of better 
health campaigns, healthcare and preventives to atten-
uate the impact of obesity. This paper describes the 
design and protocol of the BARICO study.
MEthods And AnAlysIs
study population
Patients who have been screened and found eligible for 
BS based on the Fried guidelines will be asked to partic-
ipate.52 In total, 150 patients will be included in the 
study. Study-specific inclusion criteria are: (A) patients 
willing to perform neuropsychological tests, complete 
self-report questionnaires and sign an informed consent 
document; (B) ages between 35 and 55 years; and (C) 
patients must undergo RYGB. A laparoscopic antecolic 
antegastric RYGB procedure will be performed (biliopan-
creatic limb of 150 cm, alimentary limb of 100 cm). Exclu-
sion criteria for this study are: (A) previous or current 
neurological or severe psychiatric illness; (B) pregnancy; 
and (C) treatment with any antibiotics, probiotics or 
prebiotics 3 months before or at any point during the 
study (excluding preoperative prophylaxis). A subgroup 
of 75 patients will be included in the MRI substudy, extra 
inclusion criteria for this group are: (D) patients willing 
to undergo MRI scanning and perform tasks in the MRI 
scanner; and (E) right handed (more homogeneous 
sample and less variance). The standard exclusion criteria 
for the MRI subgroup include: (F) claustrophobia; (G) 
epilepsy; (H) pacemakers and defibrillators; (I) nerve 
stimulators; (J) intracranial clips; (K) infraorbital or 
intraocular metallic fragments; (L) cochlear implants; 
(M) ferromagnetic implants; (N) circumference above 
the MRI space capacity; and (O) colour blindness. The 
study is registered at the Netherlands Trial Register ( trial-
register. nl: NTR7288).
study design
At several time points (4–8 weeks preoperative; 6, 24 
months; and 5, 10 years postoperative (figure 1)), a 
number of cognitive tests and questionnaires will be 
performed, and their results assessed. Furthermore, 
blood (after 8 hours period of fasting) and faecal matter 
will be collected from all patients (n=150) (blood at 
all time points, faeces 4–8 weeks preoperative, 6 and 
24 months postoperative (figure 1)). Intraoperatively, 
several tissue biopsies will be collected and processed. 
Medical evaluation, including anthropometric measure-
ments and information on comorbidities, will be assessed 
4–8 weeks preoperative and during all postoperative 
time points. A schematic overview of the study is shown 
in figure 1. A subgroup of patients (n=75) will addition-
ally receive a (functional) MRI ((f)MRI) scan 4–8 weeks 
preoperative and 24 months postoperative. During the 
whole study period (10 years), patients will be contacted 
by letter and via telephone at least once a year to ensure 
the best follow-up rate.
recruitment procedures and consent
Patients are informed about the study by letter and tele-
phone at least 2 weeks prior to their standard visit (4–8 
weeks before RYGB surgery). During this visit, patients 
will individually receive more information about this 
study and its objectives. Afterwards, the researchers will 
further clarify the study and the patients can ask for addi-
tional information. If they decide to participate and fulfil 
the inclusion criteria, informed consents will be obtained. 
Although the obese population consists of more females 
than males, the aim is for an equal sex distribution during 
the recruitment period (ie, a study population consisting 
of >30% men and >30% women).1 Recruitment will take 
place between August 2018 and August 2020.
outcome measures
The primary outcome measures are the neuropsycholog-
ical test scores, CBF values, hippocampal volume, mean 
diffusivity (MD) and fractional anisotropy (FA) (repre-
senting respectively grey and white matter integrity), and 
blood oxygen level dependent (BOLD) responses during 
the Stroop task. Combining neuroimaging and neuropsy-
chological tests will give us more information on how and 
whether structural brain changes are related to functional 
brain changes. Secondary measures comprise (histo-
pathologically and biochemically determined) health 
status of the collected tissue, gut microbiota composition 
changes (in jejunal mucosa and faeces) and the profiling 
of circulating mediators in blood (plasma and serum), as 
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well as lifestyle and dietary habits in relation to cognitive 
function and brain structure. Combining information 
on the pathological state of liver, gut, adipose tissue and 
circulating mediators from corresponding plasma/serum 
samples, obtained prior to and at surgery, will provide 
insight into organ crosstalk and allow identification of 
biomarker signatures for metabolic health. Differences 
in metabolic health of the subjects may be associated 
with specific signalling molecule profiles, which may be 
related to cognitive function.
(Functional) MrI
Subjects will be scanned in a 3T MAGNETOM Skyra MR 
scanner (Siemens, Healthcare Sector, Erlangen, Germany) 
using a 32-channel head coil. The MRI protocol included: 
a T1-weighted 3D magnetisation-prepared rapid gradi-
ent-echo sequence for anatomical reference and analysis 
(TR/TI/TE 2300/1100/3.03 ms; 8° flip angle; voxel size: 
1.0×1.0×1.0 mm), a fluid-attenuated inversion recovery 
sequence for white matter lesion visualisation (TR/TI 
5000/1800 ms; voxel size: 1.0×1.0×1.0 mm) and diffu-
sion-weighted MRI scans using simultaneous multislice 
echo planar imaging for probing microstructural proper-
ties (repetition time/echo time (TR/TE) 3275/91.4 ms; 
voxel size: 1.9×1.9×1.9 mm; 6× b=0 s/mm2, 42× b=900 s/
mm2, 83× b=1800 s/mm2). To allow for offline distortion 
correction of the images, seven more b=0 s/mm2 volumes 
will be acquired using the exact same sequence parame-
ters—except for the inverted k-space read-out trajectory. 
An ASL sequence will be used for quantification of CBF 
(TR/TE 2500/12 ms; voxel size: 4.0×4.0×4.0 mm) and a 
multiband, multiecho planar imaging sequence will be 
used to measure BOLD contrast during the Stroop task 
(TR/TE 1500/12.4, 34.3, 56.2 ms; 75° flip angle; voxel 
size: 2.5×2.5×2.5 mm; field of view 210 mm; 51 trans-
versal slices in interleaved order). The complete scan-
ning protocol takes 45 min and for both time points, the 
same: MR scanner, head coil and sequences will be used. 
Following the project MRI quality assurance is guaran-
teed by regular phantom measurements.
Cognitive assessment
Cognitive performance of all participants will be tested 
using an extensive neuropsychological test battery as 
detailed below. To assess general cognitive performance 
the Montreal Cognitive Assessment (MoCA) will be 
used.53 To test attentional functions, the Flexibility subtest 
from the Tests of Attentional Performance (2.3) will 
be used.54 This flexibility task focuses on shifting atten-
tion between objects. Working memory will be assessed 
via the Digit Span subtest from the Dutch language 
version of the Wechsler Adult Intelligence Scale-Fourth 
Edition.55 Participants will have to repeat a series of digits 
in forward or backward order, or sort them numerically. 
The Controlled Oral Word Association Test (COWAT) 
will be used to determine verbal fluency.56 Participants 
have to come up with as many words beginning with three 
designated letters within 60 s (for each letter). Episodic 
memory will be assessed via the immediate and delayed 
Story Recall subtest from the Rivermead Behavioural 
Memory Test.57 To control and correct for differences in 
premorbid intelligence between participants, verbal IQ 
will be estimated using the Dutch version of the National 
Adult Reading Test at baseline.58 The MoCA, episodic 
Figure 1 Overview of the study design. Blood samples are taken during a regular blood withdrawal at six time points (4–8 
weeks before BS, BS, 6 months after BS, 24 months after BS, and 5 and 10 years after BS). Microbiota analyses will be 
performed at set time points on the faeces (collected at home by the patients) (4–8 weeks before BS, 1 week before BS, 6 
months after BS, 24 months after BS) and mucosal swabs (collected during surgery). Furthermore, biopsies of liver, jejunum 
and adipose tissue depots (subcutaneous, mesenteric and omental) will be collected during surgery. Before surgery (4–8 weeks 
before BS) and at several time points after (6 months after BS, 24 months after BS, and 5 and 10 years after BS), a medical 
evaluation will take place and all patients will complete questionnaires and neuropsychological measurements to test cognitive 
function. A subgroup of patients (n=75) will be examined with MRI (4–8 weeks before BS and 24 months after BS). BS, bariatric 
surgery.
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memory test and COWAT have parallel versions, to avoid 
material-specific learning effects during the repeated 
testing. Additionally, the tests are standardised, have 
been validated for use across a wide age range and have 
good retest reliability. Together, these tests will provide a 
good overview on the overall cognitive performance of 
the patients, including aspects of working and episodic 
memory, attention, verbal fluency and executive func-
tion. Also, education level will be recorded in accordance 
with the Dutch education system using seven categories 
(1 being the lowest level of education and 7 being the 
highest).59
Assessment of biological measurements
At several time points (figure 1), fasting (at least 
8 hours) blood samples from the participants will be 
collected. As standard procedure, classical parameters, 
such as several vitamins (vitamin B12, vitamin D and folic 
acid) and lipids (triglycerides and cholesterol), will be 
measured. Special interest is taken on circulating medi-
ators of organ crosstalk, such as cytokines, oxylipids, 
adipokines, hormones and inflammation markers (eg, 
C-reactive protein, serum amyloid A, vascular cell adhe-
sion molecule 1, transforming growth factor beta), as 
well as metabolites (derived from organs or microbiota) 
assessed by metabolomics, such as bile acids and bioac-
tive (short-chain) fatty acids, and other lipid species 
(untargeted lipidomics).
Besides blood samples, faeces will be collected 
(figure 1) using ‘faeces collection kits for at home’ in 
order to monitor gut microbiota changes and relate them 
to cognition and brain structure and function read-outs. 
Additionally, to gain insight into the microbiota in the 
intestinal mucosa, mucosal swabs will be collected during 
surgery within the jejunum (two places; 150 and 250 cm 
from Treitz ligament) and stomach pouch.
As metabolically active organs such as the liver and 
adipose tissue interact directly and indirectly with the 
brain, biopsies of these organs will be collected and anal-
ysed on histopathological and biochemical level. Tissue 
biopsies will be collected from subcutaneous, mesenteric 
and omental adipose tissue, liver and jejunum. Tissue 
biopsies from these organs will be taken to assess poten-
tial pathophysiological processes and to eventually define 
mechanism-based subgroups.
Questionnaires
At several time points (figure 1) standardised question-
naires on lifestyle, education, success rate of the surgery 
and eating habits will be assessed. Most of the question-
naires are routine practice for patients undergoing BS at 
the Rijnstate Hospital. Physical activity will be assessed via 
the Baecke questionnaire and depressive symptoms will 
be assessed with the Beck Depression Inventory II.60 61 
To estimate the participants’ food/nutrient intake and 
eating behaviour patients will be asked to fill out an eating 
diary of 2 days (a weekday and a weekend day). Quality of 
life will be evaluated with the Short-Form 36.62 Lastly, the 
results of BS will be evaluated via the Bariatric Analysis 
and Report Outcome System.63
More specifically, the Barratt Impulsivity Scale-1164 and 
Behavioural Inhibition/Activation System65 question-
naires on impulsivity and reward sensitivity are included 
as reward sensitivity and impulsivity have both previously 
been suggested to contribute to overeating.66 Indeed, 
some facets of impulsivity and reward sensitivity have 
shown to be relevant in eating and weight regulation.67
Medical evaluation
At several time points during the study (figure 1) a 
medical evaluation will take place where anthropometric 
measurements, such as body weight, length, waist circum-
ference and blood pressure, will be quantified. BMI 
will be calculated as weight divided by height in metres 
squared. Percentage excess weight loss (%EWL) (defined 
as weight loss divided by preoperative excess weight, with 
excess weight defined as the weight above a normal BMI 
of 25 kg/m2) will be calculated during the time points 
after surgery, similar to percentage total body weight loss 
(%TBWL) (defined as weight loss divided by preoperative 
weight). The success of BS in terms of weight loss will be 
defined as a sustained weight loss larger than 50 %EWL.
Furthermore, data on comorbidities like T2DM, HT 
and DL and associated medication will be collected 
before the surgery and at all time points after surgery. 
Comorbidities will be defined using the following criteria: 
for T2DM a fasting plasma glucose of ≥7.0 mmol/L and 
HbA1c≥48 mmol/mol (HbA1c≥6.5%) or the use of oral 
antidiabetic or insulin medication; for HT the use of anti-
hypertensive drug treatment; for DL the use of statins.
data management
Data management will be handled using Research 
Manager (Cloud 9 Health Solutions©), an established 
software package and data management tool that follows 
Good Clinical Practice guidelines.68 Every change in the 
data is recorded in a log system and can be traced. Partic-
ipants will be identified only by a study-specific identifica-
tion code. One researcher will keep a separate participant 
identification code list that matches the study-specific 
identifying codes with the participant’s names. Docu-
ments will be maintained by the investigator in strict 
confidence.
sample size
The power calculation for the neuropsychological 
tasks was based on the results of the Digit Span subtest 
performed in a comparable study population.19 With 
an expected standardised effect size of at least 0.3 and a 
correlation of 0.7, a selected sample of 150 patients will 
be sufficient to reach 90% power. The power calculation 
for the MRI parameters is based on changes in the FA 
parameter studied by Zhang et al.51 With an expected 
standardised effect size of at least 0.03 and a correlation 
of 0.5 including 75 patients in the MRI group will be 
sufficient to reach 90% power. A significance level based 
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on the sequentially rejective multiple testing procedure 
discussed by Bretz et al (for the neuropsychological tests 
3% and for the MRI parameters 2%) has been taken into 
account in the power calculation.69 The inclusion of 150 
patients with a subgroup of 75 for the MRI scan has been 
considered adequate to answer the research questions 
with sufficient power.
Analysis of primary outcome measures
As a primary outcome measure, baseline levels of 
the imaging parameters (such as MD and FA) will be 
compared with the results of the neuroimaging outcome 
24 months after surgery (including %TBWL as a factor in 
the model). Next, the scores of the cognitive tests from 
five different time points will be analysed and compared 
with %TBWL. Every dependent variable will be modelled 
in a separate linear mixed model. %TBWL will be used 
as a factor. Different variables, such as depression score, 
age and gender, will be (if appropriate) included in the 
model. For each model, we will decide which variables to 
include as a factor to reduce the amount of unexplained 
variation. To correct for multiple outcome measures, 
the sequentially rejective multiple testing procedure 
described in Bretz et al will be used (more information 
in the online supplementary material).69 Data will be 
analysed using SPSS (V.25 for Windows) and R (V.3.5.1 
for Windows). For the cognitive tests and the imaging 
parameters, a p value <0.03 and <0.02, respectively, will be 
considered as statistically significant.
Analysis of secondary outcome measures
As secondary outcome measures, the metabolic and 
histopathological parameters (obtained analyses from 
tissues collected during surgery) will be analysed 
cross-sectionally to examine correlations between and 
among each other, and in relation to brain function and 
structure. Furthermore, potential mechanisms under-
lying the crosstalk along the gut-brain axis will be inves-
tigated by longitudinal analyses focusing on establishing 
correlations between brain structure/function changes 
and changes in circulation mediators or faecal micro-
biota composition. Pearson correlation analysis will 
be used to investigate potential correlations between 
variables.
data monitoring
Every year, data monitoring and auditing will be 
conducted by an independent specialised monitor from 
the Rijnstate Hospital. Yearly, a summary of the progress 
will be submitted to the ethical committee and the Neth-
erlands Trial Register ( trialregister. nl: NTR7288).
Patient and public involvement
Patients and the public were not involved in the design of 
this study. Nevertheless, the results will be disseminated 
to the study participants via email, newsletters and social 
media platforms after the study results are published.
dIsCussIon
The BARICO study is a prospective study focusing on 
the effect of weight loss on cognitive function and brain 
structure after BS. This will be measured using sensitive 
neuropsychological tests covering the most important 
domains, (f)MRI activation during the Stroop task and 
several MRI techniques, such as DTI and ASL. To clarify 
the impact of metabolic dysfunction in obesity on brain 
function and structure, blood plasma and stool samples 
will be collected and analysed longitudinally, and biop-
sies of key metabolic organs will be collected during the 
RYGB and analysed cross-sectionally.
After BS, there have only been a limited number of 
long-term studies demonstrating improvement in several 
cognitive domains, including memory, attention and 
executive function.18 19 Furthermore, it has been shown 
that obese individuals have lower grey and white matter 
volumes, and altered white matter densities, in compar-
ison to healthy individuals with several studies showing 
a rapid recovery of these brain structural abnormalities 
after BS.50 51 For instance, Tuulari et al showed a causal link 
between weight loss and brain tissue recovery.50 Approx-
imately 25%–30% of the patients are not expected to 
reach sufficient weight loss (≤50 %EWL), and thus it will 
be possible to study the effect of weight loss after BS on 
brain function and structure.
Perhaps the strength of this study is in the long follow-up 
duration after surgery: 24 months for the neuroimaging 
parameters and 10 years for the neuropsychological tests. 
Furthermore, the strict inclusion criterion with respect 
to age range ensures a good representation of mid-life 
patients. Moreover, the majority of studies into BS 
patients are mostly composed of women, but it is equally 
important to account for the variation in fat tissue distri-
bution which is caused by differences in sex.30
Another strength of this study is the combination of 
neuroimaging and neuropsychological tests. Alongside 
the analysis of metabolic and histopathological parame-
ters (obtained in blood, organ biopsies and microbiota), 
meaning that the relation between multiple metabolic, 
neuroimaging and/or cognitive parameters can be inves-
tigated (eg, adipokines, bioactive lipids (short-chain fatty 
acids) and organ dysfunction) in a comprehensive way. 
Since RYGB influences gut-brain communication, there 
may be beneficial alterations in adipose tissue functions, 
and/or recovery of brain function and structure following 
BS.15 70 Longitudinal analyses of the microbiota, together 
with analysis of functional gut-derived metabolites in 
the circulation and cognitive outcomes, may allow for 
the identification of mediators derived from gut micro-
flora that are relevant to cognition and the prevention of 
cognitive decline.
The BARICO study has the potential to be the first 
to demonstrate interactions between the periphery and 
central nervous system after weight loss in humans, in 
particular it will question the roles and involvement of 
the brain, and adipose tissue, liver and gut microbiota, 
after weight loss caused by BS.
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In conclusion, the BARICO study will reveal the relation 
and underlying mechanisms between obesity and brain 
function and structure. This information can be used to 
develop better healthcare as well as possible preventives 
against obesity and associated disorders.
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